CBOE Holdings Inc.

05/18/2019 | Press release | Distributed by Public on 05/18/2019 18:38

Medicines Company New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to[...]

Cboe - Market News Story

Medicines Company New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years

Charles Gross 5/18/2019 6:57:23 PM

The Medicines Company (NASDAQ: MDCO) today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density lipoprotein cholesterol (LDL-C) by more than 50 percent with overall follow-up of up to three years. Inclisiran was well tolerated, and no material safety issues were observed in the study. These results were presented today during a late-breaking clinical trial session at the National Lipid Association (NLA) Scientific Sessions in Miami.

Inclisiran, the first cholesterol-lowering therapy in the siRNA class, is in Phase 3 clinical development to evaluate its ability to lower LDL-C through twice-a-year dosing. Pivotal Phase 3 readouts for inclisiran are expected in the third quarter. ORION-3 (n=382) is an open-label extension study of the Phase 2 ORION-1 trial to assess the efficacy, safety and tolerability of long-term dosing of inclisiran.

'The cumulative effects of elevated LDL-C over time continue to place millions of people with atherosclerosis at increased cardiovascular risk, despite the widespread use of LDL cholesterol-lowering treatments,' said John J.P. Kastelein, M.D., Ph.D., ORION-3 study chair and Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, The Netherlands. 'These new data from ORION-3 provide further evidence of inclisiran's unprecedented ability to deliver persistent LDL-C reductions over a prolonged period, which can help more patients reliably achieve LDL-C goals. Inclisiran also demonstrated a favorable safety profile, an important consideration given the long duration of LDL-C treatment.'

In this interim analysis of ORION-3, inclisiran demonstrated a 51 percent (64.0 mg/dL, p<0.001) reduction in LDL-C levels through day 210, which was the study's primary endpoint. The time-averaged absolute LDL-C reduction with inclisiran was 59.4 mg/dL (p<0.001). These effects were independent of dose level and number of doses of inclisiran previously given in the ORION-1 study.

With overall follow-up of approximately three years from the first dose in ORION-1, no change in the overall safety profile was observed in this interim analysis of ORION-3 compared to the one-year follow-up in ORION-1. Inclisiran was well tolerated and no material safety issues were observed, including no elevations of liver enzymes or changes in renal function considered related to study medication. Clinically relevant injection site reactions were infrequent, mild or moderate, and transient, in line with observations in ORION-1.

'The strong data from ORION-3 bolster our confidence in inclisiran's robust therapeutic profile which offers a vastly different value proposition compared to any other LDL-C lowering option,' said Mark Timney, Chief Executive Officer of The Medicines Company. 'We truly believe that inclisiran could be a game-changer in cardiovascular care, providing simplicity and confidence to the treating physician and the treated patient that LDL cholesterol is lowered.'

'These new results reinforce that the potent, durable and consistent LDL-lowering effects of inclisiran continue over the long term with twice-a-year dosing that we believe can address the challenges of treatment adherence through improved therapeutic coverage and persistence,' said Peter Wijngaard, Ph.D., Chief Development Officer of The Medicines Company. 'We also remain encouraged by inclisiran's safety profile.'

More than 3,000 patient-years of inclisiran safety data have been accumulated to date in the ORION program. The data from ORION-3, as well as ongoing review of blinded data to date from the Phase 3 trials, show no material safety issues; data are at least as favorable as those generated and published from the ORION-1 Phase 2 trial.